:
The management of cardiovascular disease (CVD) remains a predominant challenge in modern medicine, particularly among patients who exhibit elevated levels of low-density lipoprotein cholesterol (LDL-C) and for whom existing therapeutic options are inadequate. The recent pivotal BROADWAY and BROOKLYN Phase 3 clinical trials conducted by NewAmsterdam Pharma illuminate the potential of obicetrapib as an innovative oral, non-statin lipid-lowering therapy. This article delves into the results of these trials, which highlight significant reductions in LDL-C levels and a favorable trend in the reduction of major adverse cardiovascular events (MACE), offering hope for improved management of atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH).
Atherosclerotic cardiovascular disease and familial hypercholesterolemia continue to pose significant public health concerns, necessitating treatment modalities that effectively lower LDL-C levels a recognized risk factor for cardiovascular events. The introduction of non-statin therapeutics like obicetrapib offers a potential new avenue for patients who have either experienced side effects from statins or have not achieved desired LDL-C levels with current therapies.
Methods:
The BROADWAY and BROOKLYN trials were designed to assess the efficacy of obicetrapib in patients at elevated risk of CVD and those diagnosed with HeFH. Participants continued their maximally tolerated lipid-modifying therapies. The primary endpoint for both studies was the least squares (LS) mean reduction in LDL-C compared to placebo at day 84, with sustained assessment until day 365.
Results:
BROADWAY Clinical Trial
Obicetrapib demonstrated a statistically significant reduction in LDL-C at day 84 when compared to placebo (p
Comments